Neuroferritinopathy: Update on clinical features and pathogenesis

Current Drug Targets

Volumn 13, Issue 9, 2012, Pages 1200-1203

  McNeill, Alisdair ^a   Chinnery, Patrick F ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Ferritin light chain; Magnetic resonance imaging; Neuroferritinopathy

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN; FERRITIN LIGHT CHAIN; PEPTIDES AND PROTEINS; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RESVERATROL; TETRABENAZINE; UNCLASSIFIED DRUG;

ARTICLE; AUTOSOMAL DOMINANT DISORDER; BLEPHAROSPASM; CHOREA; DYSTONIA; EXON; EXTRAPYRAMIDAL SYNDROME; FIBROBLAST; GENE EXPRESSION; GENETIC LINKAGE; HUMAN; IRON CHELATION; MISSENSE MUTATION; NEUROFERRITINOPATHY; NONHUMAN; OXIDATIVE STRESS; PARKINSONISM; TIC; WRITER'S CRAMP;

ADOLESCENT; ADULT; HUMANS; IRON METABOLISM DISORDERS; NEUROAXONAL DYSTROPHIES; YOUNG ADULT;

EID: 84864568526     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012802002375     Document Type: Article

References (23)

1. Curtis AR, Fey C, Morris CM, et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult onset basal ganglia disease. Nat Genet 2001; 28: 350-4.
2. Chinnery PF, Crompton DE, Birchall D, et al. The clinical features and natural history of neuroferritinopathy caused by the FTL1 460insA mutation. Brain 2007; 130: 110-9.
3. Devos D, Tchofo J, Vuillaume, et al. Clinical features and natural history of neuroferritinopathy caused by the 458dupA FTL mutation. Brain 2009; 132: e109.
4. Maciel P, Cruz VT, Constante M, et al. Neuroferritinopathy: missense mutation in FTL causing early-onset bilateral pallidal involvement. Neurology 2005; 65: 603-5.
5. Mancuso M, Davidzon G, Kurlan RM, et al. Hereditary Ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. J Neuropathol Exp Neurol 2005; 64: 280-94.
6. Vidal R, Ghetti B, Takao M, et al. Intracellular ferritin accumulation in neuronal and extra-neuronal tissues characterises a neurodegenerative disorder associated with a mutation in the ferritin light polypeptide gene. J Neuropath Exp Neurol 2004; 63: 363-80.
7. Ondo WG, Adam OR, Jankovic J, Chinnery PF. Dramatic response of facial stereotype/tic to tetrabenazine in the first reported cases of neuroferritinopathy in the United States. Mov Disord 2010; 25: 2470-2.
8. Kubota A, Hida A, Ichikawa Y, et al. A novel ferritin light chain gene mutation in a japanese family with neuroferritinopathy: description of clinical features and implications for genotypephenotype correlations. Mov Disord 2009; 24: 441-5.
9. Ohta E, Nagasaka T, Shindo K, et al. Neuroferritinopathy in a Japanese family with a duplication in the ferritin light chain gene. Neurology 2008; 70: 1493-4.
10. Ory-Magne F, Brefel-Courbon C, Payoux P, et al. Clinical phenotype and neuroimaging findings in a French family with hereditary ferritinopathy (FTL498-499insTC). Mov Disord 2009; 24: 1676-83.
11. Crompton DE, Chinnery PF, Fey C, et al. Neuroferritinopathy: a window on the role of iron in neurogeneration. Blood cells Mol Dis 2002; 29: 522-31.
12. Baraibar MA, Muhobera BB, Garringer HJ, Hurley RD, Vidal R. Unraveling of the E-Helices and disruption of 4-fold pores are associated with iron mishandling in a mutant ferritin causing neurodegeneration. J Biol Chem 2010; 285: 1950-6.
13. Hautot D, Pankhurst QA, Morris CM, et al. Preliminary observation of elevated levels of nanocrystalline iron oxide in the basal ganglia of neuroferritinopathy patients. Biochem et Biophys Acta 2007; 1772: 21-5.
14. Barbeito A, Levade T, Delisle M Ghetti B, Vidal R. Abnormal iron metabolism in fibroblasts from a patient with the neurodegenerative disease hereditary ferritinopathy. Mol Neurodegen 2010; 5: 50-60.
15. Cozzi A, Rovelli E, Frizzale G, et al. Oxidative stress and cell death in cells expressing L-ferritin variants causing neuroferritinopathy. Neurobiol Dis 2010; 37: 77-85.
16. Vidal R, Miravalle L, Gao X, et al. Expression of a mutant form of the ferritin light chain gene induces neurodegeneration and iron overload in transgenic mice. J Neurosci 2008; 28: 60-7.
17. Deng X, Vidal R, Englander EW. Accumulation of oxidative DNA damage in brain mitochondria in mouse model of hereditary ferritinopathy. Neurosci Lett 2010; 479: 44-8.
18. Barbeito A, Garringer HJ, Baraibar MA, et al. Abnormal iron metabolism and oxidative stress in mice expressing a mutant form of the ferritin light polypeptide gene. J Neurochem 2009; 109: 1067-78.
19. Powers JM. P53-mediated apoptosis, neuroglobulin overexpression, and globin deposits in a patient with hereditary ferritinopathy. J Neuropathol Exp Neurol 2006; 65: 716-21.
20. McNeill A, Birchall D, Hayflick SJ, et al. T2* and FSE MRI distinguishes 4 subtypes of neurodegeneration with brain iron accumulation. Neurology 2008; 70: 1614-9
21. Miglio G, Rosa AC, Rattazzi L, Collino M, Lombardi G, Fantozzi R. PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochem Int 2009; 55: 496-504.
22. Fuenzalida K, Quintanilla R, Ramos P, et al. Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J Biol Chem 2007; 282: 37006-15
23. Kairisalo M, Bonomo A, Hyrskyluoto A, et al. Resveratrol reduces oxidative stress and cell death and increases mitochondrial antioxidants and XIAP in PC6.3-cells. Neurosci Lett 2011; 488: 263-6